BPTF Warns FDA on Reduced API Manufacturer Inspections - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BPTF Warns FDA on Reduced API Manufacturer Inspections

PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

The Bulk Pharmaceuticals Task Force (BPTF), an affiliate of the Society of Chemical Manufacturers and Affiliates, issued a letter to FDA on May 27 asking that the agency ensure the frequency of inspections for any domestic API manufacturer remains consistent. 



The letter addresses the Department of Health and Human Services FY 2015 FDA budget justification disclosing that the FDA would be scaling back the number of domestic API inspections by nearly 40 percent in favor of elevating the number of foreign inspections. This action, BPTF says, could result in the failure of a number of compliant API manufacturers to receive safety inspections in a timely manner and not meet the agency's Generic Drug User Fee Amendments (GDUFA) commitment of inspecting domestic API manufacturers within a 3-year cycle. 


"We support the goal of inspection parity for both foreign and domestic API manufacturing facilities and ensuring that the FDA has the resources it needs to successfully conduct these inspections" said John DiLoreto, Executive Director of BPTF."We are simply asking the agency to ensure that, in conformance with its obligations expressed in the GDUFA Commitment Letter, the frequency of safety inspections is not compromised. The negotiated GDUFA inspection goal is to increase the frequency of foreign facility inspections, not to reduce the inspection frequency of domestic facilities"



Source: Society of Chemical Manufacturers and Affiliates

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here